Patent · US Active

Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor

US12391687B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. · CN

Inventors

Lei Jiang · Shanghai, CN
Zhiyong FENG · Shanghai, CN
Xian JIN · Shanghai, CN
Zhi Qiao · Shanghai, CN
Jianyong SHOU · Fremont, US
Ke Shang · Beijing, CN
Danyi Wu · Shanghai, CN
Lingling Xu · Qingdao, CN
Yuan Xu · Singapore, SG
Shuyun Zhang · Brookline, US
Yi Zhang · Tuji, CN
Yuxing Zhang · Ottawa, CA

Key dates

Filing date	Nov 13, 2019
Grant date	Aug 19, 2025
Priority date	—
Expiry date	Dec 21, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A class of five-membered fused with six-membered heterocyclic compounds represented by formula I and a pharmaceutical composition, preparation, and an application thereof are disclosed. These compounds have TRK kinase inhibitory activity and can treat diseases related to TRK dysfunction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.